SCHEMBL14027615

SCHEMBL14027615

CN(C)CCN(Cc1ccccc1)Cc1cccc(Cl)c1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 1/20 0.51
CAMKK2 Q96RR4 1/20 0.51
TAAR1 Q96RJ0 2/20 0.46
ALDH1A1 P00352 3/20 0.45
TSHR P16473 2/20 0.45
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
TMEM97 Q5BJF2 2/20 0.42
SIGMAR1 Q99720 2/20 0.42
BCHE P06276 1/20 0.41
ACHE P22303 1/20 0.41
P2RX7 Q99572 1/20 0.40
PNMT P11086 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CARM1 Q86X55 1/20 0.39
SLC6A2 P23975 2/20 0.38
SLC6A4 P31645 2/20 0.38
SLC6A3 Q01959 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4818525 0.89 TAAR1 (0.54) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL524817 0.80 CALM1 (0.65) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL13060693 0.79 CALM1 (0.48) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL10039140 0.78 CALM1 (0.52) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL4816296 0.78 CYP2D6 (0.56) CALM1CAMKK2ALDH1A1TSHRKDM4E
SCHEMBL15702585 0.77 TSHR (0.58) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL4823754 0.77 CALM1 (0.62) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL18157879 0.77 CALM1 (0.65) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL13005661 0.76 CALM1 (0.45) CALM1CAMKK2TAAR1ALDH1A1TSHR
SCHEMBL4823046 0.76 CALM1 (0.57) CALM1CAMKK2ALDH1A1TSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-10-30 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed
US-7375125-B2 Melanocortin-4 receptor binding compounds and methods of use thereof ORE PHARMACEUTICALS, INC. (US) 2008-05-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269217-A1 Melanocortin-4 receptor binding compounds and methods of use thereof MC4R, MC5R, MC3R CALM1 3048/4885CAMKK2 2321/4885TAAR1 216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.